Boston Scientific [BSX] vs Dexcom [DXCM] Detailed Stock Comparison

Boston Scientific Corporation

NYSE
Loading...

Dexcom Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Boston Scientific Corporation wins in 11 metrics, Dexcom Inc. wins in 8 metrics, with 0 ties. Boston Scientific Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Boston Scientific Corporation Dexcom Inc. Better
P/E Ratio (TTM) 27.49 30.03 Boston Scientific Corporation
Price-to-Book Ratio 4.02 8.63 Boston Scientific Corporation
Debt-to-Equity Ratio 48.92 50.85 Boston Scientific Corporation
PEG Ratio 0.29 0.39 Boston Scientific Corporation
EV/EBITDA 19.85 19.85 Dexcom Inc.
Profit Margin (TTM) 17.29% 17.94% Dexcom Inc.
Operating Margin (TTM) 21.55% 25.64% Dexcom Inc.
EBITDA Margin (TTM) 21.55% 25.64% Dexcom Inc.
Return on Equity 11.84% 34.50% Dexcom Inc.
Return on Assets (TTM) 6.64% 8.89% Dexcom Inc.
Free Cash Flow (TTM) $3.40B $1.08B Boston Scientific Corporation
1-Year Return -52.97% -8.07% Dexcom Inc.
Price-to-Sales Ratio (TTM) 4.74 5.10 Boston Scientific Corporation
Enterprise Value $107.72B $23.09B Boston Scientific Corporation
EV/Revenue Ratio 5.23 4.95 Dexcom Inc.
Gross Profit Margin (TTM) N/A 62.93% N/A
Revenue per Share (TTM) $14 $12 Boston Scientific Corporation
Earnings per Share (Diluted) $2.39 $2.05 Boston Scientific Corporation
Beta (Stock Volatility) 0.78 1.56 Boston Scientific Corporation
Short % of Float 1.58% 4.93% Boston Scientific Corporation

Boston Scientific Corporation vs Dexcom Inc. Stock Performance Analysis

Loading Price Chart...

BSX
DXCM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Boston Scientific Corporation-0.32%-3.98%-11.24%-33.00%-49.28%-50.63%
Dexcom Inc.-1.53%-3.13%20.43%11.88%12.92%11.54%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Boston Scientific Corporation-52.97%-13.64%9.04%108.58%590.87%133.50%
Dexcom Inc.-8.07%-42.07%-27.92%315.26%2,149.85%2,129.88%

Performance & Financial Health Analysis: Boston Scientific Corporation vs Dexcom Inc.

MetricBSXDXCM
Market Information
Market Cap i$97.63B$23.76B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i18,916,0724,652,604
90 Day Avg. Volume i16,730,7114,100,848
Last Close$46.76$74.22
52 Week Range$45.99 - $109.50$54.11 - $89.98
% from 52W High-57.30%-17.52%
All-Time High$109.50 (Sep 09, 2025)$164.86 (Nov 15, 2021)
% from All-Time High-57.30%-54.98%
Growth Metrics
Quarterly Revenue Growth0.12%0.13%
Quarterly Earnings Growth0.99%0.76%
Financial Health
Profit Margin (TTM) i0.17%0.18%
Operating Margin (TTM) i0.22%0.26%
Return on Equity (TTM) i0.12%0.35%
Debt to Equity (MRQ) i48.9250.85
Cash & Liquidity
Book Value per Share (MRQ)$16.34$7.14
Cash per Share (MRQ)$1.32$5.19
Operating Cash Flow (TTM) i$4.50B$1.44B
Levered Free Cash Flow (TTM) i$10.53B$719.54M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Boston Scientific Corporation vs Dexcom Inc.

MetricBSX (Apr 24, 2026)DXCM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i27.4930.03
Forward P/E i17.2920.59
PEG Ratio i0.290.39
Price to Sales (TTM) i4.745.10
Price to Book (MRQ) i4.028.63
Market Capitalization
Market Capitalization i$97.63B$23.76B
Enterprise Value i$107.72B$23.09B
Enterprise Value Metrics
Enterprise to Revenue i5.234.95
Enterprise to EBITDA i19.8519.85
Risk & Other Metrics
Beta i0.781.56
Book Value per Share (MRQ) i$16.34$7.14

Financial Statements Comparison: Boston Scientific Corporation vs Dexcom Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBSX (2025)DXCM (2025)
Revenue/Sales i20.07B4.66B
Cost of Goods Sold i6.22B1.86B
COGS % of Revenue i31.0%39.9%
Gross Profit i13.85B2.80B
Gross Margin i69.0%60.1%
Research & Development i2.05B599.10M
Operating Income (EBIT) i3.97B911.80M
Operating Margin i19.8%19.6%
EBITDA i5.33B1.36B
EBITDA Margin i26.6%29.1%
Pre-Tax Income i3.39B1.09B
Pre-Tax Income % of Revenue i16.9%23.3%
Income Tax i493.00M252.10M
Income Tax % of Revenue i2.5%5.4%
Net Income (Profit) i2.89B836.30M
Profit Margin i14.4%17.9%

Balance Sheet & Liquidity Metrics

MetricBSX (2025)DXCM (2025)
Cash & Equivalents i1.97B917.70M
Total Current Assets i8.79B4.03B
Total Current Assets % of Revenue i43.8%86.5%
Total Current Liabilities i5.44B2.14B
Total Current Liabilities % of Revenue i27.1%46.0%
Long-Term Debt i11.14B1.37B
Long-Term Debt % of Revenue i55.5%29.3%
Total Shareholders Equity i24.47B2.75B
Retained Earnings i5.57B2.43B
Retained Earnings % of Revenue i27.8%52.2%
Property, Plant & Equipment i077.40M

Cash Flow Statement Comparison

MetricBSX (2025)DXCM (2025)
Operating Cash Flow i4.50B1.48B
Operating Cash Flow % of Revenue i22.4%31.7%
Capital Expenditures i-876.00M-363.50M
Free Cash Flow i3.40B1.08B
FCF Margin i17.0%23.1%
Debt Repayment i-2.05B-1.21B
Common Stock Repurchase iN/A-500.00M

Short Interest & Institutional Ownership Analysis

MetricBSXDXCM
Shares Short i23.53M14.72M
Short Ratio i1.593.77
Short % of Float i1.58%4.93%
Shares Outstanding i1.49B384.80M
Float Shares i1.48B382.94M
% Held by Insiders i0.21%0.28%
% Held by Institutions i95.16%101.50%
% Held by Public i4.63%-1.78%

Dividend Analysis & Yield Comparison: Boston Scientific Corporation vs Dexcom Inc.

MetricBSXDXCM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A